Le Lézard
Classified in: Covid-19 virus

Global Respiratory Infection Diagnostic Market Research Report 2024-2028 with Executive and Consultant Guides - ResearchAndMarkets.com

The "Respiratory Infection Diagnostic Markets by Technology, Plex, Place, Product and by Region With Executive and Consultant Guides 2024-2028" report has been added to ResearchAndMarkets.com's offering.

The research makes you the expert in your organization.

COVID-19 has broken open the market for point-of-care testing of respiratory infections. Now the competition for market share begins in earnest. Large new markets are opening up. And let's not forget the screening market, not just for COVID, but for the rest of the 20-something respiratory pathogens as well. Multiplex vs single plex? Explore the rapidly changing market as competitors jockey for positions in new markets that are not yet well understood.

New technology is forever changing the diagnosis of respiratory infections. Shrinking time to results opens up markets multiple times the size of the current microbiology-based practice. The Laboratory has already moved into the Emergency Room.

The widespread nature of respiratory infections (young people can get 8 colds a year) means that potential market sizes are enormous. Respiratory, already the largest infectious disease category could multiply in size. This is a growth opportunity for all diagnostic companies. Understand the opportunity and the risk with this in-depth report.

Key Topics Covered:

1 Market Guides

1.1 Situation Analysis

1.2 Guide for Executives and Business Development Staff

1.3 Guide for Management Consultants and Investment Advisors

2 Introduction and Market Definition

2.1 What are Respiratory Infections?

2.2 The Role of Diagnosis & Treatment

2.3 Market Definition

2.4 Methodology

2.5 Perspective: Healthcare and the IVD Industry

3 Market Overview

3.1 Players in a Dynamic Market

3.1.1 Academic Research Lab

3.1.2 Diagnostic Test Developer

3.1.3 Instrumentation Supplier

3.1.4 Chemical/Reagent Supplier

3.1.5 Pathology Supplier

3.1.6 Independent Clinical Laboratory

3.1.7 Public National/regional Laboratory

3.1.8 Hospital Laboratory

3.1.9 Physicians Office Lab (POLS)

3.1.10 Audit Body

3.1.11 Certification Body

3.2 Respiratory Infections

3.2.1 Upper vs. Lower - Marketing Implications

3.2.2 Understanding the Role of Pneumonia

3.2.3 Bacterial Infections

3.2.4 Tuberculosis - A Special Case

3.2.5 Viral Infections

3.2.6 Fungal and Other Pathogens

3.3 Diagnostics - A Changing Role

3.3.1 Historical Practice

3.3.2 Current Diagnostics

3.3.3 The Multiplex Vector

3.3.4 Future Diagnostics - The Question of When and Where

3.3.5 Respiratory Infection Diagnostics - The Destination

3.3.6 Diagnostics as Defensive Weapons

3.4 COVID-19

3.4.1 Signs and symptoms

3.4.2 Transmission

3.4.3 Diagnosis

3.4.4 Prevention

3.4.5 Management

3.4.6 Prognosis

3.5 Pandemic Diagnostics

3.5.1 Risk Management - Spark and Spread

3.5.2 Dx Technology - Nucleic Acid Based

3.5.3 Dx Technology - Immunoassay & Serology

3.5.4 Time to Market and Preparedness Issues

3.5.5 Unrecognized Role of Multiplex in Pandemic Management

4 Market Trends

4.1 Factors Driving Growth

4.1.1 Syndromic Multiplexing

4.1.2 T.A.T.

4.1.3 Antimicrobial Resistance Movement

4.1.4 Pandemic Mitigation

4.1.5 An Aging at Risk Population

4.2 Factors Limiting Growth

4.2.1 The Cost Curve

4.2.2 Regulation and coverage

4.2.3 Laissez Faire

4.3 Instrumentation and Automation

4.3.1 The Shrinking Multiplexing Machine

4.3.2 Bioinformatics Networking and Anonymous Reporting

4.4 Diagnostic Technology Development

4.4.1 The Key Role of Time to Result

4.4.2 Single Cell Genomics Changes the Picture

4.4.3 Pharmacogenomics Blurs Diagnosis and Treatment

4.4.4 Pathogen Identification - A Projected Timetable of the Future

5 Respiratory Infection Diagnostics Recent Developments

5.1 Recent Developments - Importance and How to Use This Section

5.1.1 Importance of These Developments

5.1.2 How to Use This Section

5.2 Roche Gets Multiplex Emergency Use Authorization

5.3 ReadyGo Diagnostics, Gemina Labs Pursue Respiratory Market

5.4 3EO Health to Launch Molecular Point-of-Care Device

5.5 Delve Bio to Commercialize Metagenomic Pathogen Test

5.6 Sensible Diagnostics Nabs Award for Respiratory Panel

5.7 BD - FDA Clearance for Combo Respiratory Test

5.8 Co-Diagnostics Awarded for Upper Respiratory Panel

5.9 FDA Authorizes Cue Health C19 At-Home MDx

5.10 BioMerieux Waiver for Respiratory Mini Panel

5.11 Aptitude Medical Systems Aiming for At-Home Market

5.12 SD Biosensor Eyes Global Expansion For Rapid MDx System

5.13 New bioMerieux Respiratory Diagnostic System

5.14 Visby Medical Nabs FDA EUA for POC Respiratory Panel Test


5.16 Takara Bio USA, BioExcel Diagnostics Partner for Dx Panels

5.17 ProtonDx's Dragonfly Dx System successfully deployed

5.18 Genomtec Gets CE-IVD Mark for POC Respiratory Disease Test

5.19 FDA Issues First EUA for Non-Prescription COVID-19/Flu/RSV Test

5.20 "Diagnostics for the Real World" Plans Third-Generation POC Platform

5.21 Cue Health Targets DTC Market

5.22 Investors Skeptical of Ortho Clinical Diagnostics Acquisition by Quidel

5.23 Sense Biodetection to Debut Instrument-Free POC MDx

5.24 LGC Develops 'Ultra-High-Throughput' COVID Workflow

5.25 Cue Health Files for IPO for up to $100M

5.26 QuantuMDx Developing Multiplex System, Syndromic Panels

5.27 Bio-Rad Laboratories Gets CE Mark for Respiratory RT-PCR Assay Kit

5.28 BforCure Preparing Multiple Panels for PoC qPCR Platform

5.29 Angstrom Bio Raises $3M in Private Financing

5.30 Test for Them All

5.31 Hologic Banking on MDx Acquisitions

5.32 Pandemic Pushes Handheld qPCR Devices Closer to Commercialization

5.33 Talis Biomedical 2020 Revenues Rise Sharply

5.34 Luminex to Develop Covid/Flu/RSV Test

5.35 Becton Dickinson Charts Transition of COVID Diagnostics

5.36 MiRxes Receives Approval for Multiplex Covid/Flu Test

5.37 New Silicon-Based Test for Infectious Disease Screening

5.38 GenMark to Meet Demand for Respiratory Panel

5.39 Tempus Announces COVID-19 Testing, Data Initiative

5.40 Abacus Diagnostica Readying Multiplex Respiratory Test

5.41 Qiagen Acquires NeuMoDx Molecular

5.42 Companies Shift to Multiplex Tests for SARS-CoV-2, Influenza

5.43 Novacyt Gets CE Mark for Coronavirus, Flu, RSV Combo Panel

5.44 Cepheid Debuts 10-Color Technology With New Tuberculosis Test

5.45 BioMerieux's Pneumonia Panel Could Improve Care

5.46 Mammoth Biosciences Announces CRISPR-Based C19 Diagnostic

5.47 Genetic Signatures Gets CE Mark for C19 Molecular Test

5.48 Qiagen Respiratory Panel with C19 Receives CE Mark

5.49 Lumos Diagnostics Closes $15M Series A Funding

5.50 Fusion Genomics to Assess NGS Respiratory Tract Assay

6 Profiles of Key Players

6.1 Abacus Diagnostica

6.2 Abbott Laboratories

6.3 Accelerate Diagnostics

6.4 Access Bio

6.5 Ador Diagnostics

6.6 ADT Biotech

6.7 Akonni Biosystems

6.8 Altona Diagnostics

6.9 Alveo Technologies

6.10 Anatolia Geneworks

6.11 Antelope Dx

6.12 Applied BioCode

6.13 Assurance Scientific Laboratories

6.14 Aureum Diagnostics

6.15 Aus Diagnostics

6.16 Beckman Coulter Diagnostics

6.17 Becton, Dickinson and Company

6.18 Binx Health

6.19 Biocartis

6.20 BioFire Diagnostics (bioMerieux)

6.21 bioMerieux Diagnostics

6.22 Bio-Rad Laboratories, Inc.

6.23 Bosch Healthcare Solutions GmbH

6.24 Celemics

6.25 Cepheid (Danaher)

6.26 Chembio

6.27 Co Diagnostics

6.28 Credo Diagnostics Biomedical

6.29 Cue Health

6.30 Curetis N.V. / Curetis GmbH

6.31 Detect

6.32 Diagenode Diagnostics

6.33 Diascopic

6.34 Diasorin S.p.A.

6.35 Enzo Biochem

6.36 Eurofins Scientific

6.37 Fluxergy

6.38 Fulgent Genetics

6.39 Fusion Genomics.

6.40 Genetic Signatures

6.41 GenMark Dx (Roche)

6.42 Hibergene Diagnostics

6.43 Hologic

6.44 Immunexpress

6.45 Inflammatix

6.46 Invetech

6.47 Janssen Diagnostics

6.48 Karius

6.49 Lexagene

6.50 LightDeck Diagnostics

6.51 Luminex Corp

6.52 Lumos Diagnostics

6.53 Mammoth Biosciences

6.54 Maxim Biomedical

6.55 Meridian Bioscience

6.56 Mesa Biotech (Thermo Fisher)

6.57 Millipore Sigma

6.58 Mindray

6.59 Mobidiag (Hologic)

6.60 Mologic

6.61 Nanomix

6.62 Operon

6.63 Oxford Nanopore Technologies

6.64 Panagene

6.65 Perkin Elmer

6.66 Prenetics

6.67 Primerdesign (Novacyt)

6.68 Prominex

6.69 Qiagen

6.70 QuantuMDx

6.71 QuidelOrtho

6.72 Roche Molecular Diagnostics

6.73 Seegene

6.74 Siemens Healthineers

6.75 Sona Nanotech

6.76 SpeeDx

6.77 T2 Biosystems

6.78 Talis Biomedical

6.79 Thermo Fisher Scientific Inc.

6.80 Veramarx

6.81 Veredus Laboratories

6.82 Visby Medical

6.84 XCR Diagnostics

6.85 Zhejiang Orient Gene Biotech

7 The Global Market for Respiratory Infection Diagnostics

7.1 Global Market by Country

7.2 Global Market by Technology

7.3 Global Market by Plex

7.4 Global Market by Plac

7.5 Global Market by Product

8 Global Respiratory Infection Diagnostic Markets - By Technology

8.1 Microbiology

8.2 PCR

8.3 NGS

8.4 Immunoassay/Other

8.5 C19 Singleplex

9 Global Respiratory Infection Diagnostic Markets - by Plex

9.1 C19 Single Plex

9.2 Singleplex

9.3 Duplex/Triplex

9.4 Multiplex Technology

10 Global Respiratory Infection Diagnostic Markets - by Place

10.1 Hospital Lab

10.2 Outpatient Lab

10.3 POC

10.4 Other Technology

11 Global Respiratory Infection Diagnostic Markets - by Product

11.1 Instruments

11.2 Consumables

11.3 Software & Service

12 Appendices

12.1 United States Medicare System: Clinical Laboratory Fees Schedule

12.2 The Most Used IVD Assays

12.3 The Highest Grossing Assays

For more information about this report visit https://www.researchandmarkets.com/r/9n0k4n

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

These press releases may also interest you

at 13:22
Robbins Geller Rudman & Dowd LLP announces that purchasers of Nextdoor Holdings, Inc. f/k/a Khosla Ventures Acquisition Co. II publicly traded Class A common stock between July 6, 2021 and November 8, 2022, inclusive (the "Class Period"), have until...

19 avr 2024
Voxtur Analytics Corp. , a North American technology company creating a more transparent and accessible real estate lending ecosystem, is pleased to announce that it has engaged the services of ICP Securities Inc. ("ICP") to provide automated market...

19 avr 2024
On April 19, 2024, the board of directors of Portland General Electric Company declared a quarterly common stock dividend of $0.50 per share, representing an increase of 5.3%, or $0.10 per share, on an annualized basis. The company's dividend is...

19 avr 2024
Adyton Resources Corporation  ("Adyton" or the "Company") announces it has closed its previously announced non-brokered private placement offering, pursuant to which it has issued 50,000,000 common shares of the Company ("Shares") at a price of...

19 avr 2024
Building on a successful phase one in which STChealth proved that the Universal Patient Identifier (UPI)?powered by Experian Health's Universal Identity Manager (UIM) and NCPDP Standardstm?can accurately identify patients across multiple datasets in...

19 avr 2024
Lion Group Holding Ltd. ("Lion" or "the Company") , the operator of an all-in-one trading platform that offers a wide spectrum of products and services, today announced that on April 18, 2024, it received a delinquency notification letter from the...

News published on and distributed by: